Find a suitable approved and inexpensive drug that can be repurposed for evaluating anti-obesity effects in a High-Fat Diet (HFD)-induced obesity animal model, preferably rats. I am an M.Pharm Pharmacology Semester 3 student, and I need a drug candidate for my pharmacology research project. Please identify drugs based on the following criteria: 1. The drug should be already approved for another therapeutic indication and suitable for drug repurposing. 2. It should have potential mechanistic justification for anti-obesity effects, such as effects on: - appetite or food intake - lipid metabolism - fat accumulation/adipogenesis - energy expenditure - insulin resistance - inflammation - mitochondrial function - gut metabolism or other relevant metabolic pathways. 3. The drug should preferably be inexpensive and easily available in India. 4. The drug should preferably be safe and feasible for use in a student-level preclinical animal experiment, subject to institutional animal ethics approval. 5. Most importantly, conduct a careful literature search to determine whether the drug has previously been evaluated specifically for anti-obesity effects in HFD-induced obese rats or mice. 6. Prefer a drug for which there are no previous published preclinical studies, or only very limited studies, evaluating it as an anti-obesity treatment. 7. Do not claim that a drug is completely novel without checking databases such as PubMed and Google Scholar using multiple relevant search terms. 8. For every suggested drug, provide: - Drug name - Current approved indication - Why it could theoretically produce anti-obesity effects - Proposed molecular/mechanistic rationale - Evidence supporting the mechanism - Whether previous anti-obesity studies exist - Whether HFD-induced obesity animal studies exist - Novelty assessment - Possible limitations or risks - Estimated availability and affordability in India - A clear scientific justification for selecting the drug for an M.Pharm Pharmacology project. The final recommendation should have a strong scientific rationale and defensible novelty, so that I can justify the project to my research guide and Institutional Animal Ethics Committee (IAEC). Please give me 5–10 potential drug candidates, rank them according to: Novelty + Scientific Rationale + Low Cost + Availability + Feasibility for an M.Pharm Pharmacology Project. Do not simply suggest already established anti-obesity drugs. I am specifically looking for a drug repurposing candidate with a plausible mechanism but minimal or no previous direct anti-obesity evaluation in HFD-induced animal models.
Reading File
-
Candidate discovery and screening
- Identify approved, low-cost drugs with plausible metabolic, anti-inflammatory, appetite, mitochondrial, lipid-handling, or gut-metabolic mechanisms.
-
Novelty verification
- Search PubMed and Google Scholar with multiple drug-specific terms, including:
- “[drug] obesity”
- “[drug] high-fat diet”
- “[drug] HFD obese mice”
- “[drug] HFD obese rats”
- “[drug] adipogenesis”
- “[drug] insulin resistance”
- Separate direct anti-obesity studies from studies that only report metabolic markers incidentally.
- Search PubMed and Google Scholar with multiple drug-specific terms, including:
-
Mechanistic plausibility
- Assess pathways such as AMPK, PPAR signaling, adipocyte differentiation, inflammation, mitochondrial bioenergetics, insulin signaling, lipid absorption, and microbiome effects.
-
India-focused practicality
- Compare generic availability, approximate affordability, oral dosing practicality, safety concerns, handling requirements, and likely feasibility in an M.Pharm animal facility.
-
Project-design defensibility
- Build a rationale suitable for a research guide and IAEC: model selection, endpoint plan, comparator, dose-selection logic, safety monitoring, and limitations.
-
Ranked candidate shortlist
- Produce 5-10 candidates ranked by novelty, mechanistic strength, low cost, Indian availability, and feasibility, then identify the best 1-2 candidates.
A good repurposing project should not aim for an unsupported claim of “complete novelty.” The defensible target is a drug with a credible obesity-related mechanism, human approval and practical availability, but no direct HFD-obesity study or only sparse and preliminary studies. Before selecting a compound, the literature search must distinguish HFD-induced obesity experiments from diabetes, fatty liver, dyslipidemia, or cell-culture studies, because these are not equivalent evidence of anti-obesity efficacy.
For a student project, the strongest final candidate is usually an inexpensive oral generic with established animal safety information, no controlled-substance or special-storage barriers, a measurable mechanistic hypothesis, and an achievable 8-12 week HFD model design. IAEC approval still requires an institution-specific protocol, justified dose and group size, humane endpoints, and supervision by the animal facility and guide.
Rank 10 repurposing candidates for an HFD-rat study
Reading File
Reading File
Finding Sources
Searching the Web
site:pubmed.ncbi.nlm.nih.gov repurposed drugs obesity high fat diet mice rats review
Searching PubMed
"dipyridamole" AND "high-fat diet"
Searching PubMed
"cilostazol" AND "high-fat diet"
Searching PubMed
"montelukast" AND "high-fat diet"
Searching PubMed
"sulfasalazine" AND "high-fat diet"
Searching PubMed
"acetazolamide" AND "high-fat diet"
Searching PubMed
"hydroxychloroquine" AND "high-fat diet"
Searching PubMed
"fluvoxamine" AND "high-fat diet"
Searching PubMed
"pentoxifylline" AND "high-fat diet"
Searching PubMed
"memantine" AND "high-fat diet"
Searching PubMed
"colchicine" AND "high-fat diet"
Ranked screening shortlist for an HFD-induced obesity rat project
Important qualification: this is a literature-screened ranking, not a claim of absolute novelty. I searched PubMed using drug-specific HFD terms such as
"[drug] AND high-fat diet" and reviewed the resulting obesity, metabolic, and organ-specific studies. A final proposal should also document a dated Google Scholar search using drug + obesity, drug + HFD, drug + diet-induced obesity, drug + adipogenesis, and drug + rat/mouse before submission to your guide or IAEC.For an M.Pharm project, I would prioritize candidates where the hypothesis is not merely “improves lipids” but can be tested as an effect on body-weight gain, calorie intake, adiposity, glucose tolerance, insulin resistance, inflammatory adipokines, hepatic steatosis, and adipose-tissue histology.
Overall ranking
| Rank | Candidate | Approved non-obesity indication | HFD-obesity novelty status | Overall judgment |
|---|---|---|---|---|
| 1 | Montelukast | Asthma, allergic rhinitis | No direct HFD anti-obesity rodent study identified in targeted PubMed screen | Best balance of hypothesis, safety, oral feasibility, and novelty |
| 2 | Sulfasalazine | Ulcerative colitis, rheumatoid arthritis | No direct HFD anti-obesity study identified in targeted PubMed screen | Cheap and potentially novel, but mechanism is less direct |
| 3 | Acetazolamide | Glaucoma, altitude illness, selected epilepsy/edema uses | No direct HFD-obesity study identified; indirect adipogenesis evidence exists | Scientifically interesting but chronic safety is a major concern |
| 4 | Dipyridamole | Antiplatelet therapy, stroke prevention with aspirin | No direct HFD anti-obesity study identified in targeted screen | Novel, inexpensive, but mechanism needs careful framing |
| 5 | Cilostazol | Intermittent claudication due to peripheral arterial disease | HFD mouse studies for steatosis and intestinal/liver effects exist, not clearly weight-loss studies | Good mechanistic project, but less novel |
| 6 | Fluvoxamine | OCD, depression/anxiety disorders | No direct HFD-obesity study found, but appetite/weight studies in rats exist | Plausible, but CNS behavioral confounding is substantial |
| 7 | Memantine | Moderate-to-severe Alzheimer disease | HFD-containing obesity/Alzheimer mouse model and food-reward work exist | Interesting appetite-reward project, but cost and CNS confounding reduce feasibility |
| 8 | Hydroxychloroquine | Malaria, rheumatoid arthritis, systemic lupus erythematosus | Direct obesity-associated insulin-resistance and HFD studies already exist | Strong biology, weak novelty |
| 9 | Pentoxifylline | Peripheral vascular disease/intermittent claudication | Multiple HFD fatty-liver/NASH and obesity-related rodent studies exist | Suitable metabolic-inflammation work, but not a novel anti-obesity project |
| 10 | Colchicine | Acute gout, familial Mediterranean fever, pericarditis | HFD metabolic-obesity study in mice reported | Poor choice because of toxicity margin and declining novelty |
1. Montelukast - best overall candidate
Approved indication: Leukotriene receptor antagonist for asthma and allergic rhinitis.
Why it may reduce obesity-related pathology
Montelukast blocks the cysteinyl-leukotriene-1 receptor, which is relevant to inflammatory signaling in adipose tissue, macrophage infiltration, insulin resistance, oxidative stress, and potentially fatty-liver progression. In HFD obesity, chronic low-grade adipose inflammation contributes to impaired insulin signaling and ectopic lipid deposition. A CysLT1 antagonist could improve metabolic health even if its effect on body weight is modest.
Montelukast blocks the cysteinyl-leukotriene-1 receptor, which is relevant to inflammatory signaling in adipose tissue, macrophage infiltration, insulin resistance, oxidative stress, and potentially fatty-liver progression. In HFD obesity, chronic low-grade adipose inflammation contributes to impaired insulin signaling and ectopic lipid deposition. A CysLT1 antagonist could improve metabolic health even if its effect on body weight is modest.
Working molecular hypothesis
HFD → increased adipose inflammatory signaling/macrophage activation → leukotriene-mediated inflammatory amplification → TNF-alpha, IL-6, NF-kB activation, impaired insulin signaling.
Montelukast may attenuate this inflammatory axis and improve insulin sensitivity, adipokine profile, hepatic lipid accumulation, and possibly food-independent adiposity.
HFD → increased adipose inflammatory signaling/macrophage activation → leukotriene-mediated inflammatory amplification → TNF-alpha, IL-6, NF-kB activation, impaired insulin signaling.
Montelukast may attenuate this inflammatory axis and improve insulin sensitivity, adipokine profile, hepatic lipid accumulation, and possibly food-independent adiposity.
Existing supporting evidence
- Montelukast has been assessed clinically as an add-on therapy in obese people with type 2 diabetes, showing that the metabolic-inflammation concept has translational relevance, though this is not proof of an anti-obesity indication. See the 2023 randomized clinical study.
- I did not identify a direct HFD-induced obesity rat or mouse weight-loss study in the targeted PubMed search performed for this shortlist.
Novelty assessment: High to moderate.
A defensible claim would be: “The direct effect of montelukast on established HFD-induced obesity and adipose inflammation in rats appears insufficiently characterized.” Do not claim “first ever” until Google Scholar and Scopus searches are documented.
A defensible claim would be: “The direct effect of montelukast on established HFD-induced obesity and adipose inflammation in rats appears insufficiently characterized.” Do not claim “first ever” until Google Scholar and Scopus searches are documented.
Limitations and risks
- Human labeling includes neuropsychiatric safety warnings. This does not automatically preclude a rat study, but activity, behavior, and food intake could be confounded.
- A null body-weight result with improved insulin resistance would still be scientifically meaningful, but the project should be described as “anti-obesity and metabolic-protective evaluation,” not weight loss alone.
- Avoid interpreting lower food intake as proof of a direct adipose-metabolic effect.
India practicality: Widely available as generic tablets. Usually low-to-moderate cost and orally feasible.
Why select it: It offers the most defensible combination of oral feasibility, established safety pharmacology, low acquisition barrier, plausible inflammation-centered mechanism, and apparently sparse direct HFD-obesity literature.
2. Sulfasalazine - best low-cost exploratory candidate
Approved indication: Ulcerative colitis, Crohn disease in selected settings, and rheumatoid arthritis.
Why it may affect obesity biology
Obesity is associated with intestinal-barrier dysfunction, endotoxin-driven inflammation, adipose macrophage activation, and NF-kB-related insulin resistance. Sulfasalazine has anti-inflammatory actions and is cleaved in the colon, making a gut-adipose-liver axis hypothesis plausible.
Obesity is associated with intestinal-barrier dysfunction, endotoxin-driven inflammation, adipose macrophage activation, and NF-kB-related insulin resistance. Sulfasalazine has anti-inflammatory actions and is cleaved in the colon, making a gut-adipose-liver axis hypothesis plausible.
Working molecular hypothesis
Sulfasalazine may suppress NF-kB-linked inflammatory signaling, reduce inflammatory cytokines, improve intestinal inflammation/barrier-related metabolic endotoxemia, and thereby reduce adipose inflammation and insulin resistance.
Sulfasalazine may suppress NF-kB-linked inflammatory signaling, reduce inflammatory cytokines, improve intestinal inflammation/barrier-related metabolic endotoxemia, and thereby reduce adipose inflammation and insulin resistance.
Supporting rationale
- Inflammatory kinase signaling is implicated in insulin-resistant states; an HFD/insulin-resistance study has reported altered NF-kB-inducing kinase expression in mice (PMID: 22340218).
- A direct anti-obesity HFD study using sulfasalazine was not identified in my targeted PubMed search.
Novelty assessment: High.
However, it is also a higher-risk hypothesis because anti-inflammatory action does not necessarily produce loss of body fat.
However, it is also a higher-risk hypothesis because anti-inflammatory action does not necessarily produce loss of body fat.
Limitations and risks
- Potential hepatotoxicity, hypersensitivity, altered gut function, hematological effects, and folate-related effects.
- Reduced body weight could reflect gastrointestinal intolerance or reduced nutrient intake rather than beneficial metabolic remodeling.
- Requires food-intake monitoring, clinical observation, liver enzymes, complete blood count if feasible, and possibly folate supplementation considerations under veterinary/IAEC advice.
India practicality: Very inexpensive and widely available as a generic.
Why select it: Best option if the laboratory can measure inflammation and gut-liver-adipose endpoints, not just body weight. It is low cost and novel enough to support an exploratory M.Pharm dissertation.
3. Acetazolamide - high novelty, lower feasibility
Approved indication: Glaucoma, prevention/treatment of acute mountain sickness, idiopathic intracranial hypertension, and adjunct treatment in selected epilepsies.
Why it may influence fat accumulation
Carbonic anhydrases participate in bicarbonate-dependent metabolic processes. Carbonic anhydrase activity is linked with de novo lipogenesis and adipogenesis. Inhibition may reduce lipid accumulation, though the specific carbonic-anhydrase isoform and tissue context matter.
Carbonic anhydrases participate in bicarbonate-dependent metabolic processes. Carbonic anhydrase activity is linked with de novo lipogenesis and adipogenesis. Inhibition may reduce lipid accumulation, though the specific carbonic-anhydrase isoform and tissue context matter.
Working molecular hypothesis
Carbonic anhydrase inhibition → reduced bicarbonate support for lipogenic carboxylation reactions and/or reduced CA3-associated adipogenic programming → lower hepatic/adipose lipid accumulation.
Carbonic anhydrase inhibition → reduced bicarbonate support for lipogenic carboxylation reactions and/or reduced CA3-associated adipogenic programming → lower hepatic/adipose lipid accumulation.
Supporting evidence
- A rodent-focused study reported that carbonic anhydrase 3 rises during liver adipogenesis and that carbonic-anhydrase inhibitors reduced liver fat accumulation (PMID: 35108454).
- There is also a human case report associating acetazolamide with less carbonated-drink consumption and weight loss, but this is not evidence of a direct anti-obesity metabolic action (PMID: 30397500).
- I did not identify a direct acetazolamide treatment study in established HFD-induced obese rats/mice in the targeted PubMed search.
Novelty assessment: High.
Limitations and risks
- The major problem is chronic metabolic acidosis, electrolyte disturbance, diuresis, altered water intake, renal effects, and reduced appetite.
- Any apparent lower weight may be caused by fluid loss or illness, not fat-mass reduction.
- It is not my preferred first project unless your facility can monitor clinical status, water intake, electrolytes, acid-base status, and adiposity independently of body weight.
India practicality: Cheap and generally available.
Why select it: It has a mechanistically original lipid-metabolism hypothesis, but it should be selected only if the team can rule out diuresis and toxicity as explanations for apparent “anti-obesity” activity.
4. Dipyridamole - novel PDE/cAMP hypothesis
Approved indication: Antiplatelet agent, usually in combination with aspirin for secondary prevention of ischemic stroke.
Why it may have metabolic effects
Dipyridamole inhibits phosphodiesterase activity and increases extracellular adenosine signaling. Cyclic AMP signaling can influence lipolysis, thermogenesis, vascular perfusion, inflammatory signaling, and lipid metabolism.
Dipyridamole inhibits phosphodiesterase activity and increases extracellular adenosine signaling. Cyclic AMP signaling can influence lipolysis, thermogenesis, vascular perfusion, inflammatory signaling, and lipid metabolism.
Working molecular hypothesis
PDE inhibition/adenosine signaling → altered cAMP-mediated lipid handling and inflammatory signaling → reduced triglyceride accumulation or improved adipose metabolic function.
PDE inhibition/adenosine signaling → altered cAMP-mediated lipid handling and inflammatory signaling → reduced triglyceride accumulation or improved adipose metabolic function.
Supporting evidence
- Historical animal work reported lipid-lowering effects of dipyridamole in a saturated-fat-fed chick model (PMID: 21782585).
- I did not identify a direct HFD-induced obesity treatment study in rats or mice using dipyridamole in the targeted PubMed search.
Novelty assessment: Moderate to high.
Limitations and risks
- Mechanistic connection to durable reduction in fat mass is weaker than for montelukast or acetazolamide.
- Antiplatelet effects could complicate invasive procedures and terminal blood collection if technique is poor.
- A lipid-lowering effect without lower adiposity should not be presented as anti-obesity efficacy.
India practicality: Generic availability is reasonable; cost is likely low-to-moderate.
Why select it: Good for a modest “metabolic repurposing” project if you emphasize adipose/liver biochemical endpoints rather than promise major weight loss.
5. Cilostazol - good biology, limited novelty
Approved indication: Intermittent claudication due to peripheral arterial disease.
Why it may act in HFD obesity
Cilostazol is a phosphodiesterase-3 inhibitor that raises cAMP. It has reported effects on AMPK, hepatic lipid metabolism, lipoprotein lipase activity, inflammation, and gut/liver pathology.
Cilostazol is a phosphodiesterase-3 inhibitor that raises cAMP. It has reported effects on AMPK, hepatic lipid metabolism, lipoprotein lipase activity, inflammation, and gut/liver pathology.
Supporting evidence
- In rats, cilostazol lowered triglycerides and raised HDL cholesterol through increased lipoprotein-lipase activity (PMID: 10998457).
- HFD mouse studies show improvement in hepatic steatosis via AMPK/STAMP2-related mechanisms (PMID: 30366981).
- A 2024 HFD mouse study also reported attenuation of hepatic steatosis and intestinal disorders (PMID: 38892467).
Novelty assessment: Moderate to low for metabolic disease, moderate for a direct body-fat/weight-focused rat study.
Limitations and risks
- Tachycardia, vasodilatation, possible altered locomotor activity, and cardiovascular confounding.
- Existing HFD metabolic studies make a claim of novelty difficult.
India practicality: Available, though generally costlier than sulfasalazine or acetazolamide.
Why select it: A sound fall-back candidate if your guide prefers a drug with a more established mechanism and higher probability of positive metabolic findings, accepting lower novelty.
6. Fluvoxamine - appetite-centered, but confounded
Approved indication: OCD, depression, anxiety disorders.
Why it may influence obesity
Serotonergic signaling regulates satiety and food intake. Fluvoxamine may decrease food intake and weight gain by central appetite-reward mechanisms, possibly involving hypothalamic neuropeptide Y pathways.
Serotonergic signaling regulates satiety and food intake. Fluvoxamine may decrease food intake and weight gain by central appetite-reward mechanisms, possibly involving hypothalamic neuropeptide Y pathways.
Supporting evidence
- Fluvoxamine inhibited food intake and weight gain in hyperphagic Wistar rats, with hypothalamic mechanisms studied (PMID: 19043208).
- It also reduced food intake during rebound hyperphagia in rats (PMID: 9108581).
- I did not identify a direct HFD-induced obesity treatment study in the targeted PubMed search.
Novelty assessment: Moderate.
The compound is not new as an appetite-modifying drug, even if HFD-specific work is limited.
The compound is not new as an appetite-modifying drug, even if HFD-specific work is limited.
Limitations and risks
- CNS effects, stress, altered activity, and changes in anxiety-like behavior can all influence feeding.
- It is not ideal if the project’s aim is peripheral adipogenesis or lipid metabolism.
- Drug interactions and behavioral monitoring matter.
India practicality: Generic availability is usually good; low-to-moderate cost.
Why select it: Appropriate only if your central hypothesis is “modulation of hyperphagia and neurobehavioral reward pathways in HFD obesity.”
7. Memantine - food-reward candidate, but not first choice
Approved indication: Moderate-to-severe Alzheimer disease.
Why it may influence obesity
NMDA receptor signaling participates in food reward, compulsive eating, and palatable-food seeking. Memantine may decrease hedonic feeding and binge-like intake.
NMDA receptor signaling participates in food reward, compulsive eating, and palatable-food seeking. Memantine may decrease hedonic feeding and binge-like intake.
Supporting evidence
- Memantine reduced binge-like eating, food-seeking, and compulsive eating in an animal study (PMID: 25381776).
- It blunted the hedonic response to sucrose in rats (PMID: 31414153).
- A mixed HFD obesity and Alzheimer-model study is already available (PMID: 29404958).
Novelty assessment: Low to moderate.
Limitations and risks
- CNS behavioral, motor, learning, and activity confounding.
- More expensive than the leading candidates.
- HFD-related mouse literature already exists.
India practicality: Available but usually more expensive than common anti-inflammatory or respiratory generics.
Why select it: Consider only if your department has behavioral-testing capability and the project specifically focuses on hedonic feeding.
8. Hydroxychloroquine - do not select for novelty
Approved indication: Malaria; rheumatoid arthritis; systemic lupus erythematosus.
Mechanistic rationale
Anti-inflammatory, immunometabolic, insulin-sensitizing, and lipid-modulating actions. Human evidence supports favorable lipid effects, as summarized in a systematic review and meta-analysis.
Anti-inflammatory, immunometabolic, insulin-sensitizing, and lipid-modulating actions. Human evidence supports favorable lipid effects, as summarized in a systematic review and meta-analysis.
Why it ranks low
Direct obesity/HFD metabolic evidence already exists. Hydroxychloroquine improved obesity-associated insulin resistance and hepatic steatosis in preclinical work (PMID: 31427967); HFD-associated insulin-resistance work has also been reported (PMID: 27320898).
Direct obesity/HFD metabolic evidence already exists. Hydroxychloroquine improved obesity-associated insulin resistance and hepatic steatosis in preclinical work (PMID: 31427967); HFD-associated insulin-resistance work has also been reported (PMID: 27320898).
Novelty assessment: Low.
Limitations: Retinal toxicity relevance, hypoglycemia risk, immunomodulation, and existing direct literature.
Recommendation: Useful as a positive mechanistic comparator in a specialized project, not as a novel repurposing candidate.
9. Pentoxifylline - metabolic liver disease, not obesity novelty
Approved indication: Peripheral vascular disease/intermittent claudication.
Mechanistic rationale
Nonselective phosphodiesterase inhibition and anti-inflammatory effects, including TNF-alpha-related pathways, with possible benefit in steatohepatitis and vascular complications.
Nonselective phosphodiesterase inhibition and anti-inflammatory effects, including TNF-alpha-related pathways, with possible benefit in steatohepatitis and vascular complications.
Why it ranks low
- It has already been tested in HFD-induced obesity-related fatty liver in mice (PMID: 26523207).
- HFD rat work has reported improvement of NASH and early atherosclerosis through AGE/RAGE-related effects (PMID: 20835270).
- Findings may not uniformly be beneficial: pentoxifylline worsened fatty liver in obese diabetic ob/ob mice in one study (PMID: 21740407).
Novelty assessment: Low.
Recommendation: Not a good “novel anti-obesity” project. It could be used for a focused HFD-associated NASH or vascular-complication project.
10. Colchicine - avoid as an M.Pharm anti-obesity candidate
Approved indication: Acute gout, familial Mediterranean fever, and pericarditis.
Mechanistic rationale
NLRP3 inflammasome and microtubule inhibition could potentially reduce obesity-associated inflammation.
NLRP3 inflammasome and microtubule inhibition could potentially reduce obesity-associated inflammation.
Why it ranks last
- A study directly examining colchicine in HFD-induced obesity in mice has now been published (PMID: 41664375).
- A rat diet-induced hyperlipidemia study is also available (PMID: 35204113).
- The therapeutic window is narrow. Gastrointestinal toxicity, bone-marrow suppression risk, and systemic toxicity make it a poor student-level chronic-obesity candidate.
Novelty assessment: Low.
Final recommendation
Preferred drug: Montelukast
Proposed dissertation title
“Evaluation of the anti-obesity and insulin-sensitizing effects of montelukast in high-fat diet-induced obese Wistar rats: role of adipose inflammation and lipid metabolism.”
Why this is the most defensible choice
- It is an approved oral drug with broad availability as an Indian generic.
- Its inflammatory mechanism is relevant to HFD-induced adipose dysfunction and insulin resistance.
- It is not an established anti-obesity drug.
- Targeted PubMed screening did not identify a direct HFD-obesity rodent efficacy study, although this must be confirmed with a final documented Google Scholar search.
- It offers meaningful secondary outcomes even if body-weight reduction is small: insulin sensitivity, glucose tolerance, lipid profile, adipose inflammation, liver steatosis, and oxidative stress.
- It is safer and less likely to cause fluid-loss artifacts than acetazolamide, and less toxic than colchicine or sulfasalazine.
Best ultra-low-cost alternative: Sulfasalazine
Select sulfasalazine if your laboratory can support inflammation-focused assays and closely monitor tolerability. Its novelty is attractive, but the anti-obesity hypothesis is more indirect and the risk of gastrointestinal or systemic adverse effects complicating weight interpretation is greater.
Suggested core endpoints
Use an established obesity phase before treatment, rather than starting drug and HFD together. This better tests treatment of obesity rather than prevention.
- Body weight weekly
- Daily or periodic food intake
- Feed-efficiency ratio
- Waist/abdominal circumference if validated locally
- Visceral, epididymal, retroperitoneal, and mesenteric fat-pad weights
- Fasting glucose, insulin, HOMA-IR
- Oral glucose-tolerance test
- Serum triglycerides, total cholesterol, LDL-C, HDL-C
- ALT, AST and liver histology for steatosis
- Adipose histology and adipocyte diameter
- TNF-alpha, IL-6, leptin, adiponectin, and oxidative-stress markers, depending on budget
- For montelukast: adipose/liver inflammatory markers such as NF-kB, TNF-alpha, IL-6, MCP-1, and macrophage marker CD68 if facilities permit
Include a normal-diet control, HFD obese vehicle control, HFD plus test drug, and ideally an HFD plus orlistat group as a pharmacological positive control. Orlistat is a comparator, not your repurposing candidate.
Before finalizing montelukast, your proposal should explicitly state that the project tests anti-obesity-related metabolic efficacy, not a guaranteed weight-loss effect. This makes the study scientifically stronger if the drug improves insulin resistance, adipose inflammation, and steatosis without producing a dramatic fall in body weight.
This is a shared conversation. Sign in to Orris to start your own chat.